Drug Pipeline

NBI-1117568 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
5
Recruiting
4
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-16 NCT07105098
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia		 Trial sites expanded: 11 -> 15 locations
2026-05-16 NCT07114874
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia		 Enrollment reduced: 800 -> 600 participants
Active Studies by Phase
Phase 3
4
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06963034 NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Schizophrenia Recruiting
NCT07105098 NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Schizophrenia Recruiting
NCT07114874 NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia Schizophrenia Recruiting
NCT07227818 Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia Schizophrenia Recruiting
Phase 2
NCT07288320 An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With… Bipolar I Disorder Recruiting
Sponsors Running NBI-1117568 Trials
Neurocrine Biosciences (5)
Disease Areas
Schizophrenia (4) Bipolar Disorder (1)
Get alerts when NBI-1117568 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free